Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include Reglixane and Reglitazar (JAN/INN). Its PubChem CID is 154000.
Reglitazar
| CAS No | 170861-63-9 |
|---|---|
| Molecular Formula | C22H20N2O5 |
| Molecular Weight | 392.4 g/mol |
| Synonyms | 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Reglitazar, an isoxazolidine-3,5-dione derivative, is being developed by Pfizer for the treatment of diabetes. It is the first non-thiazolidenedione to enter clinical trials.
The listed CAS number is 170861-63-9.
The listed molecular formula is C22H20N2O5.
The listed molecular weight is 392.4 g/mol.
4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione.
The source lists Reglixane and Reglitazar (JAN/INN).